Stockscreener 앱 받기
33.92
0.69%
-0.165
전일 마감가:
$34.09
열려 있는:
$33.81
하루 거래량:
663.42K
Relative Volume:
0.19
시가총액:
$3.83B
수익:
-
순이익/손실:
$-99.15M
주가수익비율:
-36.48
EPS:
-0.93
순현금흐름:
$-74.25M
1주 성능:
-0.19%
1개월 성능:
-7.01%
6개월 성능:
+1.37%
1년 성능:
-3.10%
1일 변동 폭
$33.38
$34.41
1주일 범위
$32.42
$34.98
52주 변동 폭
$18.92
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
명칭
Viking Therapeutics Inc
전화
858-704-4660
주소
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
VKTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
33.91 | 3.85B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.58 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.63 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
363.38 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.67 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-29 | 개시 | Canaccord Genuity | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Goldman | Neutral |
| 2025-02-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-07 | 개시 | Citigroup | Neutral |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-11-22 | 개시 | B. Riley Securities | Buy |
| 2024-11-04 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-11 | 개시 | JP Morgan | Overweight |
| 2024-06-27 | 개시 | Morgan Stanley | Overweight |
| 2024-05-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 재확인 | Oppenheimer | Outperform |
| 2024-03-07 | 개시 | Jefferies | Buy |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2023-05-31 | 재개 | ROTH MKM | Buy |
| 2023-03-28 | 재확인 | Maxim Group | Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2021-07-29 | 재개 | BTIG Research | Buy |
| 2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 개시 | BMO Capital Markets | Outperform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-05-01 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-25 | 개시 | Stifel | Buy |
| 2019-03-29 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 재확인 | Maxim Group | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-18 | 재확인 | Maxim Group | Buy |
| 2018-09-18 | 재확인 | Raymond James | Outperform |
| 2018-07-20 | 개시 | SunTrust | Buy |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-01 | 재확인 | Laidlaw | Buy |
| 2018-05-31 | 재확인 | Maxim Group | Buy |
| 2018-03-26 | 재개 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | Maxim Group | Buy |
| 2017-11-21 | 개시 | ROTH Capital | Buy |
모두보기
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
Assessing Viking Therapeutics (VKTX) Valuation As Shares Rebound Over The Past Week - Yahoo Finance UK
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 - The Motley Fool
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts - Yahoo Finance
Viking Therapeutics (NASDAQ:VKTX) Downgraded by Zacks Research to Strong Sell - MarketBeat
2 Bargain Stocks You Can Buy for Less Than $100 Right Now - The Globe and Mail
Viking Therapeutics' Price Target of $93.39 Implies 175% Upside Potential - Intellectia AI
Viking Therapeutics (VKTX) Faces Challenges, Analysts Set Price Target of $93.39, Potential Upside of 175% - Intellectia AI
1 Stock That Could Soar by 175%, According to Wall Street - Finviz
Upcoming Oppenheimer Virtual Meeting Featuring VKTX - GuruFocus
What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026? - Finviz
3 Biotech Stocks That Look Like "Sure-Fire" Winners in 2026 - Finviz
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 - MarketBeat
Published on: 2026-01-18 12:53:17 - baoquankhu1.vn
Viking Therapeutics Stock (VKTX) Opinions on VK2735 Obesity Drug Results - Quiver Quantitative
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Volume Summary: What is AEISs valuation compared to sector2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Viking Therapeutics: A Stock at a Crossroads Amid Obesity Drug Ambitions - AD HOC NEWS
Is Viking Therapeutics (VKTX) Now Attractive After A Strong DCF Upside Signal - Yahoo Finance
Viking Therapeutics Stock Navigates a Week of High Volatility - AD HOC NEWS
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
The Escalator: AstraZeneca, Viking Therapeutics, VML Health and more - Medical Marketing and Media
M&A Speculation Fuels Rally in Viking Therapeutics Shares - AD HOC NEWS
Why Viking Therapeutics (VKTX) Is Up 6.1% After VK2735 Phase 2 Obesity Data And Phase 3 Progress - simplywall.st
Viking Therapeutics (VKTX) Soars 11.9% on Strong Weight Loss Market Outlook - Finviz
VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals - Stocktwits
Viking Therapeutics Unveils Promising Phase 2 Clinical Success, Fuels Stock Surge - timothysykes.com
Precision Trading with Viking Therapeutics Inc. (VKTX) Risk Zones - Stock Traders Daily
Viking Therapeutics (NASDAQ:VKTX) Trading 8.3% HigherShould You Buy? - MarketBeat
$VKTX stock is up 14% today. Here's what we see in our data. - Quiver Quantitative
Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals - TechStock²
SG Americas Securities LLC Acquires 81,519 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics: Positioning in the Competitive Obesity Drug Arena - AD HOC NEWS
Jim Cramer Says "I'm a Eli Lilly Guy" When Asked About Viking Therapeutics - Finviz
Jim Cramer Says “I’m a Eli Lilly Guy” When Asked About Viking Therapeutics - Insider Monkey
Viking Therapeutics Gains Investor Attention with Key Clinical Data and Strategic Positioning - AD HOC NEWS
Dow Update: Why Viking Therapeutics Inc. stock remains undervaluedMarket Risk Summary & AI Powered Market Entry Ideas - moha.gov.vn
Assessing Viking Therapeutics (VKTX) Valuation After Positive VK2735 Obesity Trial Progress - simplywall.st
Viking Therapeutics Bolstered by Clinical Data and Development Momentum - AD HOC NEWS
Appetite for weight-loss deals broader than visible, Viking CEO says - Reuters
Viking Therapeutics Gains Scientific Endorsement for Weight Loss Candidate - AD HOC NEWS
Profit Recap: Why is Viking Therapeutics Inc stock going upPrice Action & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Viking Therapeutics announces publication of results from Phase 2 VENTURE trial - TipRanks
Viking Therapeutics Announces Publication of Results from Phase - GuruFocus
New obesity drug trial sees up to 14.7% weight loss in just 13 weeks - Stock Titan
Viking Therapeutics Sharpens Commercial Focus for Obesity Drug Pipeline - AD HOC NEWS
What Investors Should Know About a Viking Therapeutics Insider's $2 Million Stock Sale - AOL.com
1 bold prediction for Viking Therapeutics in 2026 - MSN
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise - MSN
Viking Therapeutics Inc (VKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.42%
1.57%
자본화:
|
볼륨(24시간):